| value |
{"aggregator_url":"https://www.sec.gov {"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1601830/0001712276-26-000003.txt","as_of":"2026-04-09T03:12:49.786272+00:00","canonical_url":"https://www.sec.gov/Archives/edgar/data/1601830/0001712276-26-000003.txt","company":"RECURSION PHARMACEUTICALS, INC.","enrichment":{"aggregator_url":"https://www.sec.gov/Archives/edgar/data/1601830/0001712276-26-000003.txt","article_chars":1689,"article_truncated":false,"blocked_reason":null,"candidate_id":"sc_f9dc4afc12b872be","canonical_host":"sec.gov","canonical_is_aggregator":false,"canonical_url":"https://www.sec.gov/Archives/edgar/data/1601830/0001712276-26-000003.txt","content_type":"text/plain","enriched_at":"2026-04-09T19:13:33.149769+00:00","extraction_method":"heuristic","fetched_description":"","fetched_title":"","final_url":"https://www.sec.gov/Archives/edgar/data/1601830/0001712276-26-000003.txt","html_truncated":false,"paywall_likely":false,"publisher_domain":"sec.gov","publisher_resolution":"canonical_url","requested_url":"https://www.sec.gov/Archives/edgar/data/1601830/0001712276-26-000003.txt","source_event_id":"evt_93d5e45ebb48","source_quality":"medium","status_code":200,"version":"signal_enrichment_v2"},"form_type":"4","fp":"61319dea6a1beea7","kind":"sec_filing","published_at":"20260408","publisher_domain":"sec.gov","signal_understanding":{"analysis_basis":"article","claim_confidence":0.72,"dates_mentioned":["2026-04-08","2026-04-06","2014-03-05"],"entities":[{"asset_class":"equity","name":"Recursion Pharmaceuticals, Inc.","relevance":"high","symbol":"RXRX","type":"issuer"},{"asset_class":"person","name":"Taylor Ben R","relevance":"high","symbol":"","type":"reporting_owner"},{"asset_class":"person","name":"Jonathan Golightly","relevance":"medium","symbol":"","type":"signatory"}],"event_type":"listing","information_gaps":["The cleaned text does not explicitly state the number of shares acquired/sold or the transaction type (e.g., purchase, sale, vesting) beyond the tax-withholding/net settlement footnote.","No prior known state is provided in the signal, so the specific 'delta' versus prior disclosures cannot be determined from the provided text alone.","The exact transaction details (e.g., price, number of RSUs/shares involved) are not present in the provided excerpt."],"key_facts":["SEC accession number: 0001712276-26-000003.","Conformed submission type: 4 (Form 4).","Conformed period of report: 20260406.","Filed as of date: 20260408.","Reporting owner: Taylor Ben R.","Reporting owner position/title shown: Chief Financial Officer.","Issuer: Recursion Pharmaceuticals, Inc. (RXRX).","The filing includes a footnote stating: shares were withheld by the issuer to satisfy tax withholding and remittance obligations in connection with net settlement of restricted stock units.","Signature line includes: /s/Jonathan Golightly, attorney-in-fact.","Class of securities shown: Class A Common Stock."],"numeric_claims":[{"label":"Form filing date (as of)","value":"2026-04-08"},{"label":"Reporting/period date","value":"2026-04-06"}],"primary_claim":"Form 4 for RECURSION PHARMACEUTICALS, INC. was filed on 2026-04-08 (period/reporting date 2026-04-06) by reporting owner Taylor Ben R, CFO.","relevance_score":0.55,"sentiment":"neutral","source_quality":"medium","summary":"Recursion Pharmaceuticals, Inc. (RXRX) filed a Form 4 on 2026-04-08 covering a transaction dated 2026-04-06 by reporting owner Taylor Ben R (Chief Financial Officer). The filing includes a note that some shares were withheld for tax remittance in connection with net settlement of restricted stock units.","topics":["SEC Form 4","insider transaction disclosure","restricted stock units","tax withholding","net settlement"]},"source":"sec_edgar","source_domain":"sec.gov","summary":"Form 4 \u00b7 RECURSION PHARMACEUTICALS, INC. \u00b7 Filed 20260408","ticker":"RXRX","tickers":["RXRX"],"title":"RXRX filed 4","url":"https://www.sec.gov/Archives/edgar/data/1601830/0001712276-26-000003.txt"}... |